慢加急性肝衰竭诊治指南(2025 年版)

doi:10.3969/j.issn.1672-5069.2025.05.001

摘要/Abstract

摘要： 慢加急性肝衰竭是慢性肝病患者的主要死因之一,具有潜在可逆性,需要精细化的临床分型以实现精准诊治和分类管理。基于国内外最新研究成果及临床实践,中华医学会肝病学分会重型肝病与人工肝学组和中华医学会肝病学分会终末期肝病营养与再生学组组织国内有关专家联合编写了我国首部慢加急性肝衰竭诊治指南,旨在为临床实践中慢加急性肝衰竭患者的诊断、治疗和个体化管理提供指导意见。

关键词: 慢加急性肝衰竭, 诊断, 治疗, 指南

Abstract: Acute-on-chronic liver failure (ACLF) is one of the leading causes of mortality among patients with chronic liver disease. Potentially reversible, ACLF requires precise clinical classification to facilitate accurate diagnosis, targeted treatment, and comprehensive management. Based on the latest research findings and clinical evidence, the Severe Liver Disease and Artificial Liver Group and the Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association, together with multidisciplinary experts, have jointly compiled China's first guideline for the diagnosis and treatment of ACLF. The guideline aims to provide guidance for the diagnosis, treatment, and individualized management of patients with ACLF in clinical practice.

Key words: Acute-on-chronic liver failure, Diagnosis, Therapeutic, Guideline

中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025 年版)[J]. 实用肝脏病杂志, 2025, 28(5): 641-647.

Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of acute-on-chronic liver failure (2025 version)[J]. Journal of Practical Hepatology, 2025, 28(5): 641-647.

参考文献

[1] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol, 2023, 79(2): 516-537.
[2] Mak LY, Liu K, Chirapongsathorn S, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol, 2024, 21( 12): 834-851.
[3] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol, 2019, 71( 1):212-221.
[4] Br VK, Sarin SK. Acute-on-chronic liver failure: terminology, mechanisms and management. Clin Mol Hepatol, 2023, 29(3):670-689.
[5] Mezzano G, Juanola A, Cardenas A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut, 2022, 71( 1): 148-155.
[6] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南. 中华肝脏病杂志, 2006, 14(9):643-646.
[7] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南 (2012 年版). 中华肝脏病杂志 , 2013, 21(3): 177-183.
[8] 中华医学会感染病学分会肝衰竭与人工肝学组 , 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南 (2018 年版). 中华临床感染病杂志 , 2018, 11(6): 401-410.
[9] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南 (2024 年版). 中华肝脏病杂志 , 2025, 33( 1): 18-33.
[10] Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association forthe study of the liver (APASL). Hepatol Int,2009, 3( 1):269-282.
[11] Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int, 2014, 8(4): 453-471.
[12] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019, 13(4): 353-390.
[13] Choudhury A, Kulkarni AV, Arora V, et al. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int, 2025, 19( 1): 1-69.
[14] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol, 2023, 79(2):461-491.
[15] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60(1): 250-256.
[16] Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018, 67(12): 2181-2191.
[17] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
[18] Ohnishi H, Sugihara J, Moriwaki H, et al. Acute-on-chronic liver failure. Ryoikibetsu Shokogun Shirizu, 1995, (7): 217-219.
[19] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, 144(7): 1426-1437, 1437,e1-9.
[20] Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology, 2014, 147(1):4-10.
[21] Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol, 2022, 117(2):225-252.
[22] Karvellas CJ, Bajaj JS, Kamath PS, et al. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology, 2024, 79(6): 1463-1502.
[23] 徐曼曼, 李珊珊, 杨颜榕, 等. 2012 至 2021 年北京佑安医院肝衰竭住院患者流行病学特征. 中华肝脏病杂志, 2024, 32( 1):49-57.
[24] Yue T, Zhang Q, Cai T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019. Int J Infect Dis, 2022, 122:476-485.
[25] Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology, 2023, 165(4): 1025-1040.
[26] Li H, Xia Q, Zeng B, et al. Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. J Hepatol, 2015, 63(1):50-59.
[27] Baloda V, Anand A, Yadav R, et al. Histologic changes in core-needle liver biopsies from patients with acute-on-chronic liver failure and independent histologic predictors of 28-day mortality. Arch Pathol Lab Med, 2022, 146(7):846-854.
[28] Rastogi A, Maiwall R, Bihari C, et al. Two-tier regenerative response in liver failure in humans. Virchows Arch, 2014, 464(5):565-573.
[29] Xu M, Chen Y. New perspectives in the definition and classification of acute-on-chronic liver failure. Chin Med J (Engl), 2024, 137(21):2521-2525.
[30] Xu M, Kong M, Yu P, et al. Acute-on-chronic liver failure defined by Asian Pacific Association for the Study of the Liver should include decompensated cirrhosis. Front Med (Lausanne), 2021, 8:750061.
[31] Yuan H, Cao Y, Yu Z, et al. Clinical features and prognosis of acute-on-chronic liver failure in patients with recompensated cirrhosis. BMC Gastroenterol, 2023, 23( 1):319.
[32] Qiu S, Zhang Q, Hu J, et al. Impact of onset time, number, type, and sequence of extrahepatic organ failure on prognosis of acute-on-chronic liver failure. J Clin Transl Hepatol, 2024, 12(3):257-265.
[33] Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33(2):464-470.
[34] Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on theliver-transplant waiting list. N Engl J Med, 2008, 359( 10): 1018-1026.
[35] Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. HepatolInt, 2017, 11(5):461-471.
[36] Li J, Liang X, You S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. J Hepatol, 2021, 75(5): 1104-1115.
[37] Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liverfailure. J Hepatol, 2014, 61(5): 1038-1047.
[38] O'Leary JG, Reddy KR, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67(6):2367-2374.
[39] Yu Z, Zhang Y, Li Y, et al. Development of a widely applicable and simple prognostic score for patients with acute-on-chronic liver failure. J Clin Transl Hepatol, 2022, 10(5):867-878.
[40] Yu Z, Zhang Y, Cao Y, et al. A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators. Sci Rep, 2021, 11(1): 1810.
[41] Xu MM, Kong M, Yu PF, et al. Clinical course and outcome patterns of acute-on-chronic liver failure: a multicenter retrospective cohort study. J Clin Transl Hepatol, 2021, 9(5):626-634.
[42] Tandon P, Raman M, Mourtzakis M, et al. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology, 2017, 65(3): 1044-1057.
[43] Iwasa M, Iwata K, Hara N, et al. Nutrition therapy using a multidisciplinary team improves survival rates inpatients with liver cirrhosis. Nutrition, 2013, 29( 11-12): 1418-1421. D
[44] 中华医学会肝病学分会,中华医学会消化病学分会.终末期肝病临床营养指南.中华肝脏病杂志,2019,27(5):330-342.
[45] Liu X, Kong M, Hua X, et al. Effects of an individualized nutritional intervention on the prognosis of patients with liver failure. Asia Pac J Clin Nutr, 2022, 31(2): 215-221.
[46] Liu X, Kong M, Hua X, et al. Effects of an individualized nutrition intervention on the respiratory quotient ofpatients with liver failure. Asia Pac J Clin Nutr, 2019, 28(3): 428-434.
[47] Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol, 2012, 27(3): 430-441.
[48] Vaisman N, Katzman H, Carmiel-Haggai M, et al. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr, 2010, 92(1): 137-140.
[49] Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology, 2008, 48(2): 557-566.
[50] 张思琪, 陈慧娜, 耿楠, 等. 肌少症与新型慢加急性肝衰竭 5 种临床分型的关系. 西南医科大学学报 , 2024, 47( 1): 51-57.
[51] Geng N, Kong M, Zhang J, et al. Association of myosteatosis with short-term outcomes in patients with acute-on-chronic liver failure. Sci Rep, 2024, 14(1): 13609.
[52] Geng N, Kong M, Chen H, et al. Muscle function is superior to muscle mass in predicting 90-day mortality in patients with acute-on-chronic liver failure: a prospective study. Nutrition, 2024, 118:112290.
[53] Levine M, Stellpflug SJ, Pizon AF, et al. Hypoglycemia and lactic acidosis outperform King's College criteria for predicting death or transplantin acetaminophen toxic patients. Clin Toxicol (Phila), 2018, 56(7):622-625.
[54] Acharya SK, Dasarathy S, Tandon A, et al. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res, 1993, 98:69-74.
[55] 周文兴, 吕国良. 异甘草酸镁治疗慢加急性肝衰竭患者疗效观察. 中国医药, 2012, 7(8): 1046.
[56] 刘潇聪, 陈耀凯, 李晖, 等. 复方甘草酸苷对重型肝炎的治疗作用及机制研究. 第三军医大学学报 , 2009, 31( 18): 1806-1808.
[57] 毛海鹰, 滕华安, 廖礼艳, 等. 异甘草酸镁治疗重型肝炎肝衰竭疗效的 Meta 分析. 中国肝脏病杂志(电子版),2017, 9( 1): 15-19.
[58] Ye C, Li W, Li L, et al. Glucocorticoid treatment strategies in liver failure. Front Immunol, 2022, 13:846091.
[59] Jia L, Xue R, Zhu Y, et al. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. BMC Med, 2020, 18(1):383.
[60] Xu Y, Jiang Y, Li Y. Outcomes of glucocorticoid treatment in HBV-associated acute-on-chronic liver failure patients: a retrospective observational study. Turk J Gastroenterol, 2021, 32(5):473-480.
[61] Zhe-Bin W, Ke W, Mo ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101505.
[62] Shi P, Zhu WT, Liang A, et al. Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure. Acta Gastroenterol Belg, 2022, 85(4):593-600.
[63] Chen JF, Chen SR, Lei ZY, et al. Safety and efficacy of thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int, 2022, 16(4): 775-788.
[64] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志, 2019, 27( 11):846-865.
[65] 中华医学会感染病学分会. 终末期肝病合并感染诊治专家共识(2021 年版). 中华肝脏病杂志, 2022, 30(2): 147-158.
[66] 中国研究型医院学会肝病专业委员会重症肝病学组, 中华医学会肝病学分会重型肝病与人工肝学组. 重症肝病合并侵袭性真菌感染诊治专家共识. 中华肝脏病杂志, 2022, 30(2): 159-168.
[67] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会消化内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南.中华内科杂志,2023,62(1):7-22.
[68] 中华医学会肝病学分会.肝硬化腹水诊疗指南(2023年版).中华肝脏病杂志,2023,31(8):813-826.
[69] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南(2024年版).中华肝脏病杂志,2024,32(9):799-812.
[70] Nanchal R, Subramanian R, Karvellas CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. Crit Care Med, 2020, 48(3):e173-e191.
[71] Singh SA, Shrivastava P, Agarwal A, et al. LTSI Consensus guidelines: preoperative pulmonary evaluation in adult liver transplant recipients. J Clin Exp Hepatol, 2023, 13(3): 523-531.
[72] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenalsyndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74(2): 1014-1048.
[73] Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review. Gastroenterology, 2024, 166(1): 202-210.
[74] 段钟平. 人工肝脏治疗学. 北京:中国医药科技出版社, 2002.
[75] 许家璋, 段钟平. 实用人工肝及血液净化操作手册. 北京: 北京大学出版社, 2010.
[76] Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher, 2019, 34(4): 392-398.
[77] Komura T, Taniguchi T, Sakai Y, et al. Efficacy of continuous plasma diafiltration therapy in critical patients with acute liver failure. J Gastroenterol Hepatol, 2014, 29(4): 782-786.
[78] Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure. Curr Opin Crit Care, 2019, 25(2): 187-191.
[79] Liu H, Zhang Q, Liu L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Artif Organs, 2020, 44( 10):E434-E447.
[80] Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review ofcurrent clinical applications. Ther Apher Dial, 2021, 25(2): 145-151.
[81] Maiwall R, Bajpai M, Singh A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial. Clin Gastroenterol Hepatol, 2022, 20(4):e831-e854.
[82] 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022 年版). 临床肝胆病杂志, 2022, 38(4):767-775.
[83] Xu W, Zhu S, Yang L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure. J Med Virol, 2023, 95(3):e28650.
[84] Wang L, Xu W, Zhu S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: a prospective study. J Clin Transl Hepatol, 2023, 11(4):908-917.
[85] Ocak I. A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous venovenous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation. Ann Transplant, 2023, 28:e939745.
[86] 周莉, 陈煜. 人工肝治疗肝衰竭模式选择及其疗效判断标准. 中华肝脏病杂志, 2022, 30(2): 127-130.
[87] European Association for the Study of the Liver; Samuel D, De Martin E, et al. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol, 2024, 81(6): 1040-1086.
[88] 徐曼曼, 武羽, 李珊珊, 等. 不同预后评分在慢加急性肝衰竭肝移植决策中的应用. 中华肝脏病杂志 , 2023, 31(6): 574-581.
[89] Wu Y, Xu M, Duan B, et al. Acute-on-chronic liver failure: clinical course and liver transplantation. Expert Rev Gastroenterol Hepatol, 2023, 17(3): 251-262.
[90] Huebener P, Sterneck MR, Bangert K, et al. Stabilisation of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival. Aliment Pharmacol Ther, 2018, 47(11):1502-1510.
[91] Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol, 2020, 72(3):481-488.
[92] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med, 2012, 1( 10):725-731.
[93] Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure:a randomized controlled trial. Hepatology, 2017, 66(1): 209-219.
[94] Duan Z, Xin S, Zhang J, et al. Comparison of extracorporeal cellular therapy (ELAD©) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure. Hepat Med, 2018, 10:139-152.
[95] Wang Y, Zheng Q, Sun Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes. Cell Stem Cell, 2023, 30(5): 617-631.e8.